Higher mortality rate in patients with heart failure who are taking commonly prescribed antidiabetic medications and achieve recommended levels of glycaemic control

Diabetes, Obesity & Metabolism
Milton Packer

Abstract

Current guidelines for diabetes recommend that physicians attain a glycated haemoglobin (HbA1c) concentration ≤7.0%, but this target may not be applicable to those with heart failure. Fourteen studies in patients with chronic heart failure that examined the relationship between the level of HbA1c and risk of death specified whether HbA1c was influenced by treatment with antidiabetic medications. In patients with heart failure not receiving glucose-lowering drugs, the mortality rate was not higher among those with an HbA1c concentration <7.0%. By contrast, in patients who were treated with insulin, sulphonylureas and thiazolidinediones, an inverse or U-shaped relationship between HbA1c and the risk of death was generally observed, and mortality was lowest in patients with both heart failure and diabetes if the level of HbA1c was >7.0%. These studies suggest that patients with both heart failure and diabetes are at increased risk of death if they are prescribed certain glucose-lowering drugs to achieve levels of HbA1c <7.0%.

References

Jul 25, 2009·Journal of the American College of Cardiology·David AguilarAnita Deswal
Mar 31, 2012·The American Journal of Cardiology·G Sofia TomovaTamara B Horwich
Aug 26, 2014·Diabetes Research and Clinical Practice·David GrembowskiMelissa L Anderson
Dec 15, 2015·European Journal of Heart Failure·Douglas H J ElderChim C Lang
May 22, 2016·BMC Cardiovascular Disorders·Saul BleckerStuart D Katz

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Related Papers

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
Christopher J HillDamian G Fogarty
International Urology and Nephrology
Nigar SekerciogluJoanne M Bargman
Nature Clinical Practice. Cardiovascular Medicine
Paresh Dandona, Ajay Chaudhuri
© 2022 Meta ULC. All rights reserved